Celularity (CELU) Competitors

LifeVantage (NASDAQ:LFVN) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.

Do institutionals and insiders hold more shares of LFVN or CELU?

35.3% of LifeVantage shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 20.7% of LifeVantage shares are held by insiders. Comparatively, 22.1% of Celularity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the media prefer LFVN or CELU?

In the previous week, LifeVantage had 6 more articles in the media than Celularity. MarketBeat recorded 6 mentions for LifeVantage and 0 mentions for Celularity. LifeVantage's average media sentiment score of 0.57 beat Celularity's score of 0.00 indicating that LifeVantage is being referred to more favorably in the media.

Company	Overall Sentiment
LifeVantage	Positive
Celularity	Neutral

Which has higher valuation & earnings, LFVN or CELU?

LifeVantage has higher revenue and earnings than Celularity.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeVantage	$196.01M	1.11	$2.94M	$0.32	54.25
Celularity	$48.20M	1.06	-$196.29M	N/A	N/A

Does the MarketBeat Community prefer LFVN or CELU?

LifeVantage received 214 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 77.89% of users gave LifeVantage an outperform vote while only 42.11% of users gave Celularity an outperform vote.

Company	Underperform	Outperform
LifeVantage	Outperform Votes 222 77.89%	Underperform Votes 63 22.11%
Celularity	Outperform Votes 8 42.11%	Underperform Votes 11 57.89%

Is LFVN or CELU more profitable?

LifeVantage has a net margin of 2.11% compared to Celularity's net margin of -72.72%. LifeVantage's return on equity of 29.24% beat Celularity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeVantage	2.11%	29.24%	12.82%
Celularity	-72.72%	-119.53%	-25.40%

Which has more risk & volatility, LFVN or CELU?

LifeVantage has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Do analysts prefer LFVN or CELU?

LifeVantage currently has a consensus price target of $26.00, suggesting a potential upside of 49.77%. Given LifeVantage's stronger consensus rating and higher possible upside, analysts plainly believe LifeVantage is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeVantage	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Celularity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

LifeVantage beats Celularity on 15 of the 16 factors compared between the two stocks.